Copyright
©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Cardiol. May 26, 2011; 3(5): 144-152
Published online May 26, 2011. doi: 10.4330/wjc.v3.i5.144
Published online May 26, 2011. doi: 10.4330/wjc.v3.i5.144
PPARγ activator, rosiglitazone: Is it beneficial or harmful to the cardiovascular system?
Siripong Palee, Nipon Chattipakorn, Cardiac Electrophysiology Unit, Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand
Siripong Palee, Siriporn Chattipakorn, Arintaya Phrommintikul, Nipon Chattipakorn, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand
Siriporn Chattipakorn, Faculty of Dentistry, Chiang Mai University, Chiang Mai, 50200, Thailand
Arintaya Phrommintikul, Department of Medicine, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand
Author contributions: All authors contributed equally to this review.
Supported by Grants from the Thailand Research Fund RTA 5280006 (NC), BRG (SC), MRG5280169 (AP) and the Commission of Higher Education Thailand (SP, NC)
Correspondence to: Nipon Chattipakorn, MD, PhD, Cardiac Electrophysiology Research and Training Center, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand. nchattip@gmail.com
Telephone: +66-53-945329 Fax: +66-53-945368
Received: March 17, 2011
Revised: April 4, 2011
Accepted: April 11, 2011
Published online: May 26, 2011
Revised: April 4, 2011
Accepted: April 11, 2011
Published online: May 26, 2011
Core Tip